

BARDA INDUSTRY DAY 2020

October 27th, 2020 | VIRTUAL EVENT



MORNING SESSION

- 9:00 am – 9:10 am** **ASPR WELCOME!** – Dr. Robert Kadlec, M.D., MTM&H, M.S.
Assistant Secretary for Preparedness and Response
- 9:10 am – 9:20 am** **HIGHLIGHTED GOVERNMENT PARTNER** – Mr. Douglas Bryce
Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)
- 9:20 am – 9:30 am** **INDUSTRY PARTNER** –Evan Loh, M.D.
Chief Executive Office Paratek Pharmaceuticals
- 9:30 am – 9:40 am** **HIGHLIGHTED SPEAKER** – Mr. Adam Boehler, MBA
Chief Executive Officer of the new U.S. International Development Finance Corporation (DFC)
- 9:40 am – 9:50 am** **HIGHLIGHTED SPEAKER** –Michelle McMurry-Heath, M.D., PH.D
President and Chief Executive Office of Biotechnology Innovation Organization (BIO)
- 9:50 am – 10:10 am** **BARDA DIRECTOR'S UPDATE** – Dr. Gary Disbrow
Acting Director, Biomedical Advanced Research and Development Authority (BARDA)

PROGRAM OVERVIEWS

- 10:10 am – 10:20 am** **Division of Influenza and Emerging Infectious Diseases (IEID)**
Dr. Robert Johnson, *Director*
- 10:20 am – 10:30 am** **Division of Detection, Diagnostics, & Devices Infrastructure (DDDI)**
Mr. Rodney Wallace, *Director*
- 10:30 am – 10:40 am** **Division of Research, Innovation, and Ventures (DRIVE)**
Dr. Sandeep Patel, *Director*
- 10:40 am – 10:50 am** **Division of Contract Management & Acquisitions (CMA)**
Mr. Enrique Mañán, *Acting Director*
- 10:50 am – 11:00 am** **Division of Chemical, Biological, Radiological and Nuclear Medical Countermeasures (CBRN)**
Dr. Christopher Houchens, *Director*

BREAKOUT SESSION I | 11:10 am – 12:10 pm*

Track 1

- **CBRN Vaccines Program**
Lindsay Parish
- **CBRN Antivirals & Antitoxins Program**
David Boucher
- **CBRN Antibacterials Program**
Brian Tse

TRACK 2

- **Division of Clinical Development**
Robert Walker
- **Clinical Operations Branch**
Elizabeth Formentini
- **Biostatistics Branch**
James Zhou
- **Clinical Operations Branch**
Marcy Beth Grace

TRACK 3

- **Blue Knight Panel**
Moderator: Ashley Cecere
- (See attachment for more details)*

TRACK 4

- **Pharmaceutical Countermeasure Infrastructure**
- **Collaborating with our Manufacturing Partners**
Arlene Joyner
- **The National Biopharmaceutical Manufacturing Partnership (BioMaP)**
Timothy Belski

*Submit questions for LIVE Q&A following each presentation

12:30 pm – 1:30 pm

LUNCH

BREAKOUT SESSION II | 1:30 PM – 2:30 PM*

TRACK 1

- **Division of Nonclinical Development- Overview**
April Brys
Claiborne Hughes
James Little
- **SARS-CoV-2 Response Planning**
James Little
- **SARS-CoV-2 Model Development and Utilization**
Allison Totura
- **SARS-CoV-2 Assay Development**
Ashley Smith
- **BARDA Nonclinical Development- Looking Forward**
Claiborne Hughes

TRACK 2

- **Thermal Burn Medical Countermeasures Program**
Janelle Hurwitz
- **Radiological & Nuclear Countermeasures Program**
John Esker
- **Reimagining Community Preparedness for Mass Casualty Chemical Incidents**
Will Coley

TRACK 3

- **DRIVE: Investing in the Future of Health Security**
Moderator: Sandeep Patel

(See attachment for more details)

TRACK 4

- **Medical Countermeasures Development (MCM-D) Contracting**
James Harris
- **Medical Countermeasures Support Services (MCM-S) Contracting**
Jeffrey Schmidt
- **DRIVE Acquisitions Team**
Matthew-McCord
- **Station Support & Administrative Contracting (SSAC)**
Rosemary Hill

*Submit questions for LIVE Q&A following each session

2:30 am – 2:40 pm

BREAK

BREAKOUT SESSION III | 2:40 PM – 3:40 PM*

TRACK 1

- **Influenza and Emerging Infectious Disease Therapeutics: Vaccines**
Armen Donabedian
- **Influenza and Emerging Infectious Disease: Therapeutics**
Kimberly Armstrong
- **Pandemic Influenza Vaccine Stockpile**
Jonathan Seals

TRACK 2 (Session 1)

- **Regulatory and Quality Affairs, and EUA Overview**
Nina El-Badry, & Susan Hollingsworth

TRACK 2 (Session 2)

- **JPEO-CBRND**
COL Ryan Eckmeier

TRACK 3

- **CARB-X/BARDA Ventures Panel Discussion**
Moderators: Cameron Bess and Justin Yang

(See attachment for more details)

TRACK 4

- **Detection, Diagnostics, & Devices Infrastructure (DDDI) Division**
Rodney Wallace
- **Timeline, Contracting Approach, Tests Funded**
John Lee
- **Shipments & Diagnostics Manufacturing Expansion**
Charles Daitch
- **Key Lessons Going Forward**
Matthew Davenport
- **How to Prepare a Strong White Paper**
Paul Eder
- **Solicitations & Submission Status**
Jordan Smith

*Submit questions for LIVE Q&A following each session

LIGHTNING TALKS SESSIONS | 3:40 PM – 4:40 PM

SESSION I: Vaccines/Therapeutics (Approx. 10 presenters)

SESSION II: Devices/Diagnostics (Approx. 10 presenters)

WRAP UP | 4:40 PM – 4:45 PM

- Dr. Gary Disbrow

PANEL DETAILS

BLUE KNIGHT: Sparking Innovation to Improve the Nation's Response to 21st Century Health Security Threats-

Moderator: Ms. Ashley Cecere, Project Officer

Blue Knight, a joint BARDA & Johnson & Johnson Innovation-JLABS initiative, aims to stimulate innovation and incubation of technologies that improve health security by engaging companies focused on public health threats and emerging infectious diseases. This panel session will include a brief introduction to Blue Knight and include a Q&A discussion with representatives from Johnson & Johnson Innovation-JLABS, two Blue Knight companies, as well as individuals from BARDA that serve as Blue Knight Mentors.

Panel Members:

Ms. Rachel Rath

BARDA Alliance *Director,*
Johnson & Johnson Innovation
– JLABS

Dr. Stephanie Culler

CEO and Co-Founder,
Persephone Biosciences, Inc.

Dr. Lindsay Parish

Biologist, BARDA

Dr. Ariel Weinberger

CEO, Autonomous
Therapeutics, Inc.

Dr. Peter Adams

Health Scientist,
BARDA

PANEL DETAILS

DRIVE: Investing in a New Approach to Health Preparedness-

Moderator: Dr. Sandeep Patel, DRiVe Director

DRiVe is the newest BARDA Division that may not be a household name yet, but everyone in the health and life sciences industry should get to know. At the end of this plenary session, you will see how DRiVe is investing in the future of health security by innovating at the intersection of science, technology, and venture, identifying and investing in solutions to health threats today and tomorrow.

You'll hear directly from some of our partners building next-generation solutions to disease detection and sepsis prediction, and directly from the DRiVe team about our new streamlined contracting process that is enabling us to act more quickly, and our new areas of interest in ENACT, sepsis, new vaccine delivery technologies, repurposing drugs to address chemical threats, and much more.

Presenting Companies: Cytovale, Immunexpress, Inc., Sonica Health, 98point6, Inc., Evidation Health, and Beckman Coulter

Panel Members:

Mr. Matthew McCord *Chief*

Contracting Officer

Dr. ŠeilaŠ elimovic´

Program Manager

Dr. Kimberly Sciarretta

Program Manager

Ms. Donna Boston

Project Officer

Mr. Justin Yang

Director, DRiVe Catalyst Office

Dr. Kerry DeMarco

Intergovernmental and
Partnership Lead

Dr. Kumiko Lippold

Health Scientist

PANEL DETAILS

CARB-X and DRiVe Accelerator Networks: Wrap Around Services to Prepare for Competitive Funding Engagements-

Moderators: Mr. Justin Yang, Interface Office Lead and Dr. Cameron Bess, Biologist

BARDA, through the CARB-X and DRiVe programs, is supporting a network of wrap-around-service-oriented accelerators that can be leveraged to assist partners in all aspects of their technology development including providing business, legal, regulatory, and product specific expertise and advice. This panel of BARDA supported accelerators will describe their "wrap-around services" and innovators and product developers will discuss how this support has led to improved outcomes.

Panel Members:

Dr. Erin Duffy

Chief of R&D for CARB-X

Dr. Keith Bostian´

Dean, Kean University

Mr. James LaTorre

Chief Executive Officer,
Lytica

Dr. Rida Mourtada

Chief Science Officer, Lytica

Dr. Mark Stidham

Director, Evotec

Dr. Eric Bacqu 

Vice President, Evotec

Ms. Diane Rucker

Executive Director, University
Enterprise Laboratories

Mr. Kris Khalil

Interim President &
Managing Director, New
Orleans BioInnovation
Center

Dr. Mehdi Javanmard

Chief Executive Officer,
Rizlabs Health